AIDS

Vaccine to be developed will be directed against multiple HIV antigens

Published in Vaccine Weekly, June 11th, 2003

BioVex announced that it has signed a letter of intent with the Vaccine Research Center at the National Institutes of Allergy and Infectious Disease, National Institutes of Health, in relation to the development of an HIV vaccine utilizing BioVex's proprietary ImmunoVEX, herpes simplex-based platform.

The vaccine will incorporate a combination of VRC's HIV antigen genes aimed at maximizing the immune response to the virus.

The development of the vaccine will be governed by a Collaborative Research and Development Agreement (CRADA). BioVex will provide an ImmunoVEX HIV vaccine construct to the VRC, which will test the vaccine in preclinical...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2003-06-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry